Most of this latest interview with CEO Richard Schumacher features him covering the capabilities and very high research value of the Pressure BioSciences technology. Towards the end he also touches on the significantly improved company financing and revenue growth that has recently taken place. The elimination of company debt combined with rising revenues in 2016 is setting PBIO up for a banner year in 2017. This company is also raising cash from the investment side and planning for a higher public investor profile with a return to a NASDAQ listing.
You don't find this good a package in many stocks at this very buyable pps level.
News 
Market Data 
Discover 
